O&G SAQs · Antenatal care — haematological disorders
Haemoglobinopathies in pregnancy — structured SAQ (15 marks)
FRANZCOG-format structured SAQ on sickle cell disease in pregnancy: MDT pathway and LMWH prophylaxis, the sickle crisis bundle with analgesia within 30 minutes and acute chest syndrome recognition, transfusion strategy with phenotypic matching, and postpartum contraception. Per-sub-part marking rubric included.
On this page
Study tools
Target exams
How this SAQ is marked
Twelve SAQs, 180 marks, two 2-hour papers — roughly 15 marks and 20 minutes each. Marks come from specifics: named drug, dose, route, threshold, monitoring interval. Write in short labelled points, not prose paragraphs. Answer the sub-part you are asked. [1]
Reveal model answer and mark schemeShowHide
(a) Antenatal plan (5 marks)
One mark per point, maximum five. [1][2]
- Multidisciplinary team: haematology, obstetrics, anaesthetics, midwifery, with a named lead and joint clinic. Counsel on the raised maternal and perinatal risks (Oteng-Ntim Blood 2015 meta-analysis: maternal mortality RR 5.98, pre-eclampsia RR 2.43, stillbirth RR 3.94, SGA RR 3.72, preterm RR 2.21).[1][2]
- Thromboprophylaxis: low-molecular-weight heparin (e.g. enoxaparin 40 mg daily) throughout pregnancy, dose-adjusted for weight and renal function, continued for 6 weeks postpartum.[1]
- Surveillance: serial growth scans every 4 weeks from 24 weeks; low threshold for admission in crisis; midstream urine each trimester; vaccination status (pneumococcus, meningococcus, haemophilus, hepatitis B, influenza).[1]
- Medications: folic acid 5 mg daily (lifelong in HbSS); review hydroxyurea — discontinue preconception and avoid in pregnancy.[1]
- Plan delivery: in a unit with haematology, anaesthetics and neonatal support; avoid prolonged labour; keep warm, well hydrated and oxygenated; continuous fetal monitoring; regional anaesthesia preferred.[1]
(b) Acute chest syndrome (5 marks)
One mark per point, maximum five. [1]
- Diagnosis: acute chest syndrome — fever, pleuritic chest pain, hypoxia (saturation 92 percent) and new infiltrates on chest X-ray in a sickle cell disease patient. The leading cause of sickle cell mortality.[1]
- Analgesia within 30 minutes: morphine 5 to 10 mg intravenously, titrated; patient-controlled analgesia in established crises. Avoid pethidine (metabolite lowers seizure threshold).[1]
- Oxygen to maintain saturation above 94 percent or above baseline; incentive spirometry every 2 hours while awake to prevent atelectasis.[1]
- Broad-spectrum antibiotics covering encapsulated organisms (functional asplenia) and atypicals (e.g. ceftriaxone plus azithromycin) after blood cultures.[1]
- Transfusion for severe or worsening hypoxia — simple transfusion to raise Hb, or exchange transfusion to reduce HbS below 30 percent if hypoxia is severe, worsening or with multilobar involvement. Phenotypically matched blood from the start.[3]
(c) Transfusion strategy (3 marks)
One mark per point, maximum three. [1][3]
- Indications: severe anaemia (Hb well below baseline), acute chest syndrome, stroke, splenic sequestration, perioperative cover. Prophylactic transfusion is not routine in most uncomplicated sickle cell pregnancies — transfuse on indication.[1][3]
- Phenotypic matching: extended phenotypically matched blood (ABO, Rh, Kell, Kidd, Duffy) from the first transfusion to limit alloimmunisation, which is common and dangerous in sickle cell disease.[3]
- Risks: alloimmunisation, delayed haemolytic transfusion reaction (DHTR), iron overload, transfusion-transmitted infection. Identify preformed antibodies early in pregnancy.[3]
(d) Postpartum contraception (2 marks)
One mark per point, maximum two. [1][5]
- Progestogen-only methods are safe in sickle cell disease — progestogen-only pill, depo-medroxyprogesterone, progestogen implant, levonorgestrel intrauterine system.[1][5]
- Combined hormonal contraception is generally avoided because of the raised VTE risk in sickle cell disease, but may be considered in well-controlled, non-smoking women after individual risk assessment. The levonorgestrel intrauterine system is an excellent option.[5]
References6ShowHide
- [1]Oteng-Ntim E, Pavord S, Howard R, et al. Management of sickle cell disease in pregnancy. A British Society for Haematology Guideline Br J Haematol, 2021.PMID 34409598
- [2]Oteng-Ntim E, Meeks D, Seed PT, Webster L, Howard J, Doyle P, Chappell LC Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis Blood, 2015.PMID 25800049
- [3]Chou ST, Alsawas M, Fasano RM, Field JJ, Hendrickson JE, Howard J, Kameka M, Kwiatkowski JL, Pirenne F, Shi PA, Stowell SR, Thein SL, Westhoff CM, Wong TE, Akl EA American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support Blood Adv, 2020.PMID 31985807
- [4]Boulet SL, Okoroh EM, Azonobi I, Grant A, Craig Hooper C Sickle cell disease in pregnancy: maternal complications in a Medicaid-enrolled population Matern Child Health J, 2013.PMID 23315242
- [5]Howard RJ, Lillis C, Tuck SM Contraceptives, counselling, and pregnancy in women with sickle cell disease BMJ, 1993.PMID 8343632
- [6]Taher AT, Iolascon A, Matar CF, Bou-Fakhredin R, de Franceschi L, Cappellini MD, Barcellini W, Russo R, Andolfo I, Tyan P, Gulbis B, Aydinok Y, Anagnou NP, Bencaiova GA, Tamary H, Martinez PA, Forni G, Vindigni R Recommendations for Pregnancy in Rare Inherited Anemias HemaSphere, 2020.PMID 32885142